New Joint Infection Treatment Shows Trial Data

Adults with infected hip or knee replacements may soon have a seven-day alternative to lengthy revision surgery, pending further trial results.

Updated on Nov. 5, 2026 in Arthritis

New Joint Infection Treatment Shows Trial Data

Osteal Therapeutics will present three scientific studies on treating periprosthetic joint infection, a serious infection that can follow hip or knee replacement, at the 2026 AAHKS Annual Meeting in Grapevine, Texas, November 5-8. The company's presentations include 24-month outcomes from its APEX randomized clinical trials, relevant to patients and surgeons dealing with infected joint replacements.

Why it matters

Periprosthetic joint infection is a difficult complication, and current two-stage exchange surgery is long and has a success rate under 50% after 12 months, so new options are being closely watched. The presentations matter now because they bring longer-term follow-up data from randomized trials to a major orthopedic audience.

The data come from two randomized controlled trials, APEX and APEX-2, enrolling 152 patients with chronic periprosthetic joint infection of the hip or knee at 23 U.S. centers. The presentations will report 24-month treatment outcomes, though specific results are not included in the announcement and the product remains investigational.

The players

Osteal Therapeutics

A clinical-stage biopharmaceutical company developing combination drug/device therapies for orthopedic infections, including NEXCHANGE KIT.

Nicolas S. Piuzzi, MD

An orthopedic surgeon at Cleveland Clinic presenting 24-month outcomes from the APEX and APEX-2 trials.

AAHKS

The American Association of Hip and Knee Surgeons, the professional society hosting the 2026 annual meeting where the research is being presented.

U.S. Food and Drug Administration

The federal agency that has granted NEXCHANGE KIT Breakthrough Therapy, Orphan Drug, Fast Track, and Qualified Infectious Disease Product designations.

The details

NEXCHANGE KIT is an investigational combination of a drug and a device that delivers the antibiotics vancomycin and tobramycin directly into the joint space and surrounding tissue during an exchange arthroplasty procedure. The approach, called cyclic local antibiotic irrigation, aims to reach the infection at the site rather than relying only on systemic antibiotics. The treatment is a seven-day therapy, in contrast to the roughly 16-week timeline of two-stage exchange arthroplasty.

Timeline

  1. November 5-8, 2026: AAHKS Annual Meeting in Grapevine, Texas, where the presentations will be given

  2. November 5, 2026: Osteal Therapeutics announced the scheduled presentations

Health Landscape

Two-stage exchange arthroplasty has long been the standard for treating periprosthetic joint infection, but its lengthy timeline and under-50% success rate after 12 months leave room for alternatives. The FDA's Breakthrough Therapy and Fast Track designations place NEXCHANGE KIT within an expedited pathway aimed at this unmet need.

If you have had a hip or knee replacement and are concerned about infection symptoms such as persistent pain, swelling, or drainage, worth raising with your surgeon promptly. Patients considering revision surgery for a joint infection may want to ask their orthopedic team whether investigational options are appropriate for their situation.

The takeaway

New data on joint infection treatment will be presented to surgeons this November, and the 24-month APEX results are worth following as they are published. If you have concerns about a replaced joint, discuss them with your orthopedic surgeon before the next scheduled follow-up.

What happens next

The APEX presentations are scheduled for the AAHKS Annual Meeting, November 5-8, 2026, in Grapevine, Texas.

Further reading

For broader context on joint conditions, explore our Arthritis coverage.

More information

Learn more on the Osteal Therapeutics company website.

Source note: This article includes information reported by The Manila times.